Forced to Act: Omnitrope and the Battle for an FDA Commissioner
This article was originally published in RPM Report
Executive Summary
Generic biologics was not a priority for Andrew von Eschenbach when he accepted the job as acting commissioner of FDA. But two events -- a federal court ruling requiring a decision on Sandoz' Omnitrope NDA and the European Union approval of the follow-on biologic -- mean FDA may be pressed to take action on a regulatory pathway. The Omnitrope ruling makes it more important than ever that FDA have a fully confirmed leader in place, but it will also make it harder to get one.
You may also be interested in...
Coming to Terms with the FDA Commissioner
The Institute of Medicine thinks FDA needs more stability at the highest level, and thinks a six-year fixed term for the commissioner is a good solution. But FDA's new commissioner doesn't agree.
Coming to Terms with the FDA Commissioner
The Institute of Medicine thinks FDA needs more stability at the highest level, and thinks a six-year fixed term for the commissioner is a good solution. But FDA's new commissioner doesn't agree.
Plan B Approval Is Good News for OTC Switch of Xenical
FDA's fitful handling of Barr's OTC switch application for the emergency contraceptive Plan B has provided great political theater. But for GSK and Roche, the issue was a complication for the OTC switch of the weight loss drug orlistat. Now the path looks clear.